Two Sigma Advisers LP Makes New Investment in Danaher Co. (NYSE:DHR)

Two Sigma Advisers LP bought a new position in Danaher Co. (NYSE:DHR - Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 37,700 shares of the conglomerate's stock, valued at approximately $10,481,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. CarsonAllaria Wealth Management Ltd. purchased a new stake in shares of Danaher during the 2nd quarter valued at $25,000. nVerses Capital LLC purchased a new stake in shares of Danaher during the 2nd quarter valued at $25,000. Teachers Insurance & Annuity Association of America purchased a new stake in shares of Danaher during the 3rd quarter valued at $39,000. MidAtlantic Capital Management Inc. purchased a new stake in shares of Danaher during the 3rd quarter valued at $40,000. Finally, FSA Wealth Management LLC purchased a new stake in shares of Danaher during the 3rd quarter valued at $50,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Down 0.7 %

NYSE:DHR traded down $1.57 during mid-day trading on Tuesday, hitting $234.34. 2,753,249 shares of the company's stock were exchanged, compared to its average volume of 2,778,954. Danaher Co. has a one year low of $217.96 and a one year high of $281.70. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The business has a fifty day moving average price of $249.91 and a 200 day moving average price of $258.14. The company has a market cap of $169.26 billion, a PE ratio of 44.72, a P/E/G ratio of 4.23 and a beta of 0.83.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the firm posted $2.02 earnings per share. Danaher's quarterly revenue was up 3.1% on a year-over-year basis. Equities analysts predict that Danaher Co. will post 7.5 EPS for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.46%. Danaher's dividend payout ratio (DPR) is presently 20.61%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. UBS Group lowered their price objective on shares of Danaher from $309.00 to $305.00 and set a "buy" rating on the stock in a research report on Wednesday, October 23rd. Wolfe Research upgraded shares of Danaher from a "peer perform" rating to an "outperform" rating and set a $285.00 target price on the stock in a research report on Thursday, October 31st. KeyCorp lifted their target price on shares of Danaher from $290.00 to $310.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 23rd. Stifel Nicolaus lifted their target price on shares of Danaher from $250.00 to $265.00 and gave the stock a "hold" rating in a research report on Wednesday, October 23rd. Finally, TD Cowen lifted their target price on shares of Danaher from $310.00 to $315.00 and gave the stock a "buy" rating in a research report on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $287.16.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.